Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
In the p53 knockout cell line HCT-116 p53–/–cell line, MI-1061 has an IC50>10000 nM, but in the SJSA-1 and HCT-116 p53+/+ cell lines, it obtains IC50=100 and 250 nM, respectively[1].
|
---|---|
ln Vivo |
In the SJSA-1 xenograft tumor model in mice, MI-1061 (100 mg/kg; po; daily for 14 days) can cause tumor regression[1].
|
Animal Protocol |
Animal/Disease Models: SCID (severe combined immunodeficient) mouse bearing SJSA-1 osteosarcoma xenografts[1]
Doses: 100 mg/kg Route of Administration: Po; daily for 14 days Experimental Results: Demonstrated strong antitumor activity and achieved significant tumor regression. |
References |
[1]. Aguilar A, et al. Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles. J Med Chem. 2014;57(24):10486-10498.
|
Molecular Formula |
C32H27CL2F4N3O6
|
---|---|
Molecular Weight |
696.47
|
CAS # |
1410737-35-7
|
Related CAS # |
MI-1061;1410737-34-6
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
C1=CC(C(=O)O)=CC=C1NC([C@@H]1NC2(CCCCC2)[C@@]2(C(=O)NC3=CC(Cl)=CC=C23)[C@H]1C1=CC=CC(Cl)=C1F)=O.OC(=O)C(F)(F)F
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 120 mg/mL (172.30 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (4.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (4.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.4358 mL | 7.1791 mL | 14.3581 mL | |
5 mM | 0.2872 mL | 1.4358 mL | 2.8716 mL | |
10 mM | 0.1436 mL | 0.7179 mL | 1.4358 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.